Lawsuit in Hawaii against Plavix Sponsors Alleges Burden is on Pharma to Market PGx Information | GenomeWeb

Can drugmakers be held liable for failing to aggressively warn consumers that patients with certain genetic markers will not respond or will have limited response to their drugs beyond just mentioning this information in drug labeling? This is the issue at the heart of the lawsuit that Hawaii Attorney General David Louie has brought against Plavix manufacturers Bristol-Myers Squibb and Sanofi-Aventis.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.